Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

t. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (File No. 333-145638), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

BCRXW

BIOCRYST PHARMACEUTICALS, INC.

FINANCIAL SUMMARY

Statements of Operations (Unaudited)

(in thousands, except per share)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenues:

Collaborative and other

research and development $8,894 $20,463 $22,321 $43,066

Expenses:

Research and development 15,996 29,730 51,267 64,938

General and administrative 2,471 2,595 8,023 6,980

Total expenses 18,467 32,325 59,290 71,918

Loss from operations (9,573) (11,862) (36,969) (28,852)

Interest and other income 578 878 2,167 2,080

Net loss $(8,995) $(10,984) $(34,802) $(26,772)

Basic and diluted net

loss per common share $(0.24) $(0.32) $(0.91) $(0.86)

Weighted average shares

outstanding 38,095 34,277 38,040 31,024

Balance Sheet Data (in thousands)

September 30, December 31,

2008 2007


'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Boston, MA (PRWEB) September 30, 2014 On ... Director James Sherley in anticipation of a session that ... -organized “Predictive Toxicology Summit,” scheduled for February 17-18, 2015 in ... September 15, Pharma IQ asked Dr. Sherley to respond to ... stem cell toxicity, challenges to evaluating stem cell toxicity, and ...
(Date:9/30/2014)... 30, 2014 Back in the 1970’s, many ... feet. per employee, which included space for circulation and file ... Jeff Howell, partner at Nidea Corporate Real Estate / ... “By the year 2000, however, 250 square feet per ... number come down to 175 to 225 square feet, and ...
(Date:9/29/2014)... diagnostics today, with imaging techniques like MRI (magnetic ... (nuclear magnetic resonance) increasing steeply over the last ... and quality still limit these techniques because of ... hyperpolarization, which involves injecting the patient with substances ... distribution and fate of specific molecules in the ...
(Date:9/29/2014)... Research and Markets  has announced the addition of ... End-User , Application - Global Forecast to 2019" ... oligonucleotide synthesis market is expected to reach $1,712.1 million ... a CAGR of 9.8% from 2014 to 2019. The ... of products and services, applications, end users, and geography. ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3
... NORTH VANCOUVER, BC, July 23 /PRNewswire-FirstCall/ - Chromos ... that the,securities commissions or similar regulatory authorities in ... Quebec have revoked the,cease trade orders against the ... are currently no cease trade orders outstanding against ...
... Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA) ("Duska") announced ... of a proposed Phase 3 clinical study for,its ... Drug Administration,s (the,"FDA") Division of Cardiovascular and Renal ... FDA, including a face-to-face,meeting held on April 16, ...
... 23 Tengion Inc., a clinical,stage biotechnology company focused ... it has appointed Mark Stejbach as Vice,President, Marketing and ... marketing, sales, finance, and managed care experience from,both Merck ... very pleased to welcome Mark to the Tengion executive ...
Cached Biology Technology:Chromos Announces Full Revocation of Cease Trade Orders 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 3Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 4Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning 2
(Date:9/30/2014)... Ludwig-Maximilians-Universitaet (LMU) in Munich report that a new ... sensitive to chemotherapeutic drugs. They have also pinpointed ... target for anti-tumor agents. , Researchers led ... Sieber of the Technische Universitt Mnchen have identified ... new weapon in the fight against malignant tumors. ...
(Date:9/30/2014)... Sept. 30, 2014  Spectra Automation, a ... the biotech and power generation industries, announced ... Bioprocess Manager, an easy-to-use and cost-effective data ... bioprocess development laboratories. Most ... and analyzer systems. Accessing and consolidating data ...
(Date:9/29/2014)... called Clostridium ramosum , coupled with a high-fat diet, ... this week in mBio , the online open-access journal ... team from the German Institute of Human Nutrition Potsdam-Rehbruecke in ... C. ramosum gained weight when fed a high-fat diet. ... less obese even when consuming a high-fat diet, and mice ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... Thanks to laws of elementary electrostatics, we can easily ... and therefore predict their movements. Submerge those particles ... the calculation grows more complex. The charged particles, movements ... or otherwise alter the particles, paths. In this environment ...
... Kevlar and other synthetic fabrics: Step aside. If new ... blouses and other garments made from fibers modeled after ... called the hagfish. The study appears in ACS, journal ... supervisor Douglas S. Fudge and colleagues explain that petroleum ...
... Mainz, Germany and the renowned School of Medicine at ... This strategic partnership promises to provide an innovative stimulus ... University Medical Center. The resulting regular exchange will benefit ... "Our aim is to arrive at a better ...
Cached Biology News:Outside a vacuum: Model predicts movement of charged particles in complex media 2Mainz University Medical Center agrees partnership with Yale University 2
... patented technology, the Lone Wolf valve has ... Open proportional valve available on the market. ... repeatable high-speed performance, and ensures maximum accuracy., ... Enhances system control and patient comfort. , ...
... is the smallest electronic pressure controller ... mm. Parker configured this unit specifically for ... markets. Used in carrier gas flow control, ... dispensing, and hydro-dynamic focusing, the OEM-EPC offers ...
... The VSO LF (Low Flow) offers the same ... control for applications where control is critical or ... solenoid-operated valve automates the flow of gas in ... either DC current or pulse width modulation; closed ...
...
Biology Products: